Inactive Instrument

Intersect ENT, Inc.

Equities

XENT

US46071F1030

Medical Equipment, Supplies & Distribution

Intersect ENT, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 06, 2021 at 07:15 am EDT

Intersect ENT, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 27.349 million compared to USD 9.780 million a year ago. Operating loss was USD 16.074 million compared to USD 21.092 million a year ago. Net loss was USD 16.601 million compared to USD 23.124 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.71 a year ago. For the half year, sales was USD 51.677 million compared to USD 29.606 million a year ago. Operating loss was USD 34.648 million compared to USD 39.022 million a year ago. Net loss was USD 36.632 million compared to USD 40.657 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.25 a year ago.

Latest news about Intersect ENT, Inc.

Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Healthcare Equipment Select Industry Index	22-05-17	CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P TMI Index	22-05-17	CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Global BMI Index	22-05-17	CI
Medtronic Completes Purchase Of US Medical Device Group Intersect ENT	22-05-13	MT
Medtronic Completes Purchase of Intersect ENT	22-05-13	MT
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from NASDAQ Composite Index	22-05-13	CI
Hemostasis, LLC acquired Fiagon AG Medical Technologies from Intersect ENT, Inc.	22-05-12	CI
Medtronic plc completed the acquisition of Intersect ENT, Inc..	22-05-12	CI
Intersect ENT, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
Intersect ENT, Inc. Enters into Amendment No.1 to Facility Agreement	22-04-18	CI
Intersect ENT, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-08	CI
Intersect ENT Reports Positive Data From Real-World Evidence Study of Propel Sinus Implants	22-01-25	MT
Intersect ENT®, Inc. Announces Positive Results of Observational	22-01-25	CI
Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures From the Firm	21-12-13	MT
Intersect ENT, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-02	CI
Earnings Flash (XENT) INTERSECT ENT Reports Q3 Loss $-0.48	21-11-02	MT
Earnings Flash (XENT) INTERSECT ENT Posts Q3 Revenue $24.4M	21-11-02	MT
Transcript : Intersect ENT, Inc. - Shareholder/Analyst Call	21-10-08
Intersect ENT, Inc. Enters into Facility Agreement	21-09-27	CI
North American Morning Briefing : Blockbuster -3-	21-08-13	DJ
INTERSECT ENT : SVB Leerink Downgrades Intersect ENT to Market Perform From Outperform; Price Target is $28.25	21-08-12	MT
North American Morning Briefing : Investors Await -3-	21-08-11	DJ
INTERSECT ENT : BTIG Downgrades Intersect ENT to Neutral From Buy	21-08-10	MT
INTERSECT ENT : Canaccord Genuity Downgrades Intersect ENT to Hold from Buy, Adjusts Price Target to $28.25 from $29	21-08-09	MT
INTERSECT ENT : Berenberg Bank Adjusts Intersect ENT Price Target to $28.25 From $18, Maintains Hold Rating	21-08-09	MT

Chart Intersect ENT, Inc.

Duration

Period

More charts

Company Profile

Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-4.84%	182B
MEDTRONIC PLC	+0.56%	110B
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B
DEXCOM, INC.	+2.39%	50.53B
CENCORA, INC.	+9.36%	44.8B
HOYA CORPORATION	+2.70%	40.7B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B
TERUMO CORPORATION	+13.67%	25.02B
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B

Other Medical Equipment, Supplies & Distribution